-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Brand | Therapeutic category |
|---|---|
|
Arixtra |
Antithrombotic agent |
|
Diprivan |
General anaesthetic |
|
Fraxiparine |
Low molecular weight heparin |
|
Eltroxin |
Thyroid hormone replacement |
|
Naropin |
Regional anaesthetic |
0
Products
Launched
Launched
(2023: 3)
0
Product
Recalls
Recalls
(2023: Nil)
0
%
Average Staff
Turnover
Turnover
(2023: 22%)
0
Work-related
Facilities
Facilities
(2023: Nil)
100
*
Sales
Representatives
Representatives
(2023: 470)
1000
*
Permanent
Employees
Employees
(June 2024)
1080
*
Permanent
Employees
Employees
(June 2023)
* Excludes acquisition of Sandoz AG China business.
0
Products
Launched
Launched
(2022: 3)
Product
Recalls
Recalls
(2022: Nil)
10
%
Average Staff
Turnover
Turnover
(2022: 29%)
Work-related
Facilities
Facilities
(2022: Nil)
410
Sales
Representatives
Representatives
(2022: 535)
900
Permanent
Employees
Employees
(June 2022: 1,166)
| Revenue |
2024 R’million |
2023 (CER) R’million |
Change % |
|---|---|---|---|
|
Commercial Pharmaceuticals |
4 100 |
5 623 |
(27) |
|
Injectables |
3 112 |
4 790 |
(35) |
|
Prescription |
697 |
560 |
24 |
|
Over the counter |
291 |
273 |
7 |
|
Manufacturing |
|
|
|
|
Finished dose form |
100 |
122 |
(18) |
|
Total |
4 200 |
5 745 |
(27) |
Note: Commercial Pharmaceuticals’ revenue is by customer geography and Manufacturing revenue is by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 91
- Asia9
Revenue by segment (%)
- Injectables 74
- Prescription 17
- Over the counter 7
- Finished dose form 2
- Propofol market value in May 2024 was RMB2,54 billion, compared to RMB2,74 billion in the prior year. The market value decline is due to the implementation of Volume Based Procurement.
- Aspen’s Diprivan holds 37% as at May 2024, a decline of 1,97% compared to May 2023.
Source: China IMS CHPA Report, May 2024.
